Jiaqiang Cai
Co-founder and CSO and Co-Chief Executive Officer Medilink Therapeutics
Dr. Cai is the Co-founder, CSO and Co-CEO of MediLink Therapeutics. Before cofounding Medilink Therapeutics, Dr. Cai served as vice general manager and director of chemistry of Shanghai Hansoh Pharm. Before joining Hansoh, Dr Cai was deputy general manager of Sichuan Kelun Institute of Pharmaceutical Research responsible for small molecule drug R&D and Kelun’s innovation centre managing over 250 research scientists. Dr. Cai accumulated over 30 years of experience in drug discovery research, managed over 100 projects across different therapeutic areas with 30 compounds in different stages of clinical development, 8 of them are antibody drug conjugates, including SKB264, SKB315, YL201 and YL202.
Dr. Cai graduated from Dalian Institute of Chemical Physics with PhD degree, finished post-doctoral training at University College London. Before returning to China, Dr. Cai was senior team leader and project leader at Merck’s (MSD) UK research centre.
Seminars
- Utilizing novel linker chemistry to circumvent the need for ADC internalization for payload release
- Applying novel linker payload technology to unlock development against previously inaccessible ADC targets
- Demonstrating novel target accessibility through preclinical efficacy and safety data of anti-VEGF avastin ADC YL242
- Exploring how Topo1 and Topo1-ADCs elicit immunogenic cell stress in vivo through the induction of cellular senescence
- Delineating the host immune cell requirements for Topo1-induced immunogenicity
- Identifying biomarkers of immunogenic cell stress mediated by Topo1 ADCs
